HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
Dennis G McGonagle Selected Research
Dennis G McGonagle Research Topics
Disease
6
Psoriatic Arthritis
01/2023 - 09/2013
5
COVID-19
01/2022 - 01/2021
5
Inflammation (Inflammations)
01/2021 - 07/2008
3
Rheumatoid Arthritis
12/2023 - 12/2014
3
Necrosis
01/2020 - 01/2019
2
Arthralgia (Joint Pain)
12/2023 - 01/2018
2
Arthritis (Polyarthritis)
12/2023 - 01/2020
2
Psoriasis (Pustulosis Palmaris et Plantaris)
01/2023 - 01/2020
2
Synovitis
01/2022 - 01/2018
2
Ankylosing Spondylitis
01/2019 - 09/2013
2
Axial Spondyloarthritis
01/2019 - 09/2013
2
Edema (Dropsy)
09/2013 - 07/2008
1
Asthma (Bronchial Asthma)
12/2023
1
Uveitis
01/2023
1
Osteoarthritis
01/2022
1
Infections
01/2021
1
Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2020
1
Adult-Onset Still's Disease
01/2020
1
Pneumocystis Infections
01/2020
1
Spondylarthropathies
01/2019
1
Nail Diseases (Nail Disease)
01/2018
1
Enthesopathy
01/2018
1
Pain (Aches)
01/2018
1
Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis)
04/2016
1
Lymphoma (Lymphomas)
12/2014
1
Fibrosis (Cirrhosis)
11/2013
1
Muscular Diseases (Myopathy)
02/2012
1
Joint Diseases (Joint Disease)
12/2007
Drug/Important Bio-Agent (IBA)
4
Interleukins
IBA
12/2023 - 01/2019
4
Glucocorticoids
IBA
01/2022 - 01/2020
3
Immunologic Factors (Immunomodulators)
IBA
01/2022 - 01/2021
3
baricitinib
IBA
01/2022 - 01/2020
3
Biomarkers (Surrogate Marker)
IBA
01/2022 - 07/2008
2
tocilizumab (atlizumab)
FDA Link
01/2022 - 10/2021
2
tofacitinib
IBA
01/2022 - 10/2021
2
Antirheumatic Agents (DMARD)
IBA
01/2022 - 01/2020
2
Janus Kinase Inhibitors
IBA
01/2022 - 10/2021
2
Oxygen (Dioxygen)
IBA
01/2022 - 01/2021
2
Immunomodulating Agents
IBA
10/2021 - 01/2021
2
Cytokines
IBA
01/2021 - 01/2019
2
Antibodies
IBA
01/2021 - 02/2012
2
Interleukin-23 (Interleukin 23)
IBA
01/2020 - 11/2019
1
benralizumab
IBA
12/2023
1
Anti-Citrullinated Protein Antibodies
IBA
12/2023
1
Acute-Phase Proteins (Acute-Phase Protein)
IBA
12/2023
1
mepolizumab
IBA
12/2023
1
Rheumatoid Factor
IBA
12/2023
1
Histocompatibility Antigens Class I
IBA
01/2023
1
Aminopeptidases
IBA
01/2023
1
Indicators and Reagents (Reagents)
IBA
01/2022
1
Interleukin-1 (Interleukin 1)
IBA
01/2022
1
Interleukin-6 (Interleukin 6)
IBA
01/2021
1
Interferons
IBA
01/2021
1
Dexamethasone (Maxidex)
FDA Link
Generic
01/2021
1
apremilast
IBA
01/2020
1
Janus Kinase 1
IBA
01/2020
1
amsonic acid (DAS)
IBA
01/2020
1
Interleukin-12 (IL 12)
IBA
01/2020
1
guselkumab
IBA
01/2020
1
Interleukin-17 (Interleukin 17)
IBA
01/2019
1
Proteins (Proteins, Gene)
FDA Link
01/2019
1
Tumor Necrosis Factor Inhibitors
IBA
01/2018
1
Steroids
IBA
04/2016
1
Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
IBA
12/2014
1
HLA-B27 Antigen (HLA B27 Antigen)
IBA
09/2013
1
Cholinergic Receptors
IBA
02/2012
Therapy/Procedure
7
Therapeutics
12/2023 - 12/2007
5
Immunomodulation
01/2022 - 01/2021
1
Transplantation
01/2023
1
Knee Replacement Arthroplasty (Total Knee Replacement)
01/2022
1
Injections
01/2020
1
Biological Therapy
01/2018